Positive results from pivotal Phase III trial of new

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma

Copenhagen, 2013-07-11 08:58 CEST (GLOBE NEWSWIRE) --  

Copenhagen, Denmark; ALK (OMX: ALK.B) announces positive outcome of the second of two pivotal Phase III trials of its new allergy immunotherapy tablet for the treatment of house dust mite-induced respiratory diseases. The MITRA [1] trial meets its primary endpoint and demonstrates a significant reduction in the risk of moderate-to-severe asthma exacerbations.

Today, ALK announces positive top-line results from the pivotal Phase III MITRA trial conducted with ALK’s allergy immunotherapy tablet against house dust mite-induced respiratory diseases. The results demonstrate that the treatment significantly reduces patients’ risks of moderate to severe asthma exacerbations. The results were statistically significant (p<0.05).   

The trial also demonstrated that the treatment was well tolerated and had a favourable safety profile.   

“House dust mite-induced respiratory diseases, such as allergic rhinitis and asthma, affect more than 200 million people worldwide. Together with the successful MERIT [2] trial, these results represent a major step forward in developing the first clinically documented allergy immunotherapy tablet for patients severely impacted by house dust mite-induced respiratory diseases experiencing poor control of their condition,” says CEO Jens Bager, ALK.   

The MITRA trial (MT-04) was initiated by ALK in 2011 to evaluate the efficacy and safety of the allergy immunotherapy tablet compared to placebo in patients with house dust mite-induced asthma. The primary endpoint of the trial was reduction in the risk of moderate to severe asthma exacerbations during steroid reduction as measured by the time to the first exacerbation.   

The trial was a randomised, placebo-controlled, double-blind, multi-centre trial involving 834 patients from 13 European countries. Patients were divided into three treatment arms. Patients in the first two groups received two different doses of the tablet, while patients in the third group received placebo. Patients were dosed once daily for up to 18 months. Additionally, all patients received treatment with inhaled corticosteroids (ICS) until the last part of the trial, where the ICS usage was reduced by 50% for three months, and then completely withdrawn for another three months. The trial design and success criteria were discussed with the European Medicines Agency during a scientific advice prior to trial initiation.

House dust mites are the most common cause of allergic respiratory diseases in the world. Nearly 50% of all house dust mite-allergic rhinitis patients suffer from concomitant asthma. House dust mite-induced allergic diseases are estimated to affect around 90 million people in Europe, North America and Japan, and more than 100 million people in China. The condition appears early in life, is present all year round and the prevalence of asthma is increasing in most countries, especially among children.  

Further top-line data from the MITRA trial is expected to be presented in connection with the publication of ALK’s six-month interim report (Q2) on 14 August 2013.  

“The successful outcome of the MERIT and MITRA trials keeps us on course for a European filing in 2014. It also provides positive news for our partners’ parallel development programmes in North America and Japan, and increases our confidence that this innovative product will help fuel our future growth,” says CEO Jens Bager, ALK.  

European filing in 2014 On 19 June 2013, ALK announced robust, positive top-line results from the MERIT trial in the treatment of house dust mite-induced allergic rhinitis. The results demonstrated that the treatment reduced both symptoms and medication use in patients with house dust mite-induced allergic rhinitis. The results were highly statistically significant (p<0.01).   

In combination, the MITRA and the MERIT trials will be a pivotal part of ALK's submission of a registration application in Europe. ALK expects to submit the registration application in 2014.  

Global development programme The MERIT and MITRA trials are part of the largest clinical development programme in the history of allergy immunotherapy, with simultaneous development activities in Europe and the world’s two largest pharmaceutical markets, Japan and the USA. Once completed, this programme will have involved more than 6,000 patients.  

In Japan, ALK’s partner Torii Pharmaceutical Co., Ltd. is currently undertaking two parallel pivotal Phase II/III trials to investigate the safety and efficacy of the allergy immunotherapy tablet in the treatment of house dust mite-induced allergic rhinitis and allergic asthma, respectively.   

In North America, ALK’s partner Merck & Co., Inc. (known as MSD outside the USA and Canada) is currently performing a Phase IIb trial and has started preparations for a pivotal Phase III clinical trial to investigate safety and efficacy in the treatment of house dust mite-induced rhinitis/rhinoconjunctivitis in adolescents and adults.   

This announcement does not impact ALK’s financial guidance for 2013.   

ALK-Abelló A/S  

Jens Bager President & CEO  

 

For further information please contact : Jens Bager, President and CEO, tel. +45 4574 7576 Investor Relations: Flemming Pedersen, mobile +45 2148 0118                             Per Plotnikof, mobile +45 2261 2525 Press: Martin Barlebo, tel. +45 4574 7901 , mobile +45 2064 1143

[1] The MITRA trial: MITIZAX Treatment of Asthma trial  

[2] The MERIT trial: MITIZAX Efficacy in Rhinitis Trial  

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 74

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 66

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 107

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 407

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 181

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 481

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 473

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 689

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 744

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading

Top 5 Most Recently Viewed Articles

Rising Trends in the Office Sleep Pod Market: A Growth Story

Updated Category News Views 187

Overview of the Office Sleep Pod Market The Office Sleep Pod Market is witnessing a remarkable surge, driven by a confluence of factors centered around workplace wellness, the link between rest and employee productivity, and the incorporation of modern workplace infrastructure by global companies. The appetite for sleep pods is being fueled by stress-laden corporate...

Continue Reading
Ancient Crunch Expands into Whole Foods' 400 Stores

Updated Category News Views 28

The Move into Whole Foods: A Strategic Leap If you'd told me years ago that a snack made with beef tallow would make waves in the premium grocery market, I'd have laughed in your face. But here we are—Ancient Crunch is making a bold power play into Whole Foods Market, placing their sons of grit and gusto, MASA and Vandy, onto 400 new shelves nationwide. It's like...

Continue Reading
Acuity Brands Unveils Comprehensive Environmental Report 2024

Updated Category News Views 294

Acuity Brands Reveals its EarthLIGHT Report for 2024 ATLANTA, Dec. 10, 2024 - Acuity Brands, Inc. (NYSE: AYI), a leading industrial technology company, has published its annual EarthLIGHT Report. This document outlines significant accomplishments in Environmental, Social, and Governance (ESG) for the fiscal year 2024, while also providing insights into key strategic...

Continue Reading
RAPT Therapeutics Announces Participation in Investor Conferences

Updated Category News Views 138

RAPT Therapeutics to Engage Investors in Upcoming Conferences RAPT Therapeutics, Inc. (NASDAQ: RAPT), an innovative biopharmaceutical company based in South San Francisco, is gearing up for a series of influential investor conferences this March. The company's focus on developing cutting-edge therapies for immunological conditions positions them at the forefront of...

Continue Reading
Opus One Gold Completes Final Tranche of Private Placement Funding

Updated Category News Views 66

Opus One Gold Completes Final Tranche of Private Placement Funding Opus One Gold Corporation (OOR: TSXV) has achieved a significant milestone by wrapping up the second tranche of its private placement. This non-brokered offering has successfully drawn in substantial investment, reflecting strong market confidence in Opus One’s potential. Details of the Offering In this...

Continue Reading